EJPB
editorials
Editorial
The year of 2006 has been for the European Journal of Pharmaceutics
and Biopharmaceutics undoubtedly the most successful in its recent
history. The impactor factor increased to 2.525 according to ISI
(Institute of Scientific Information) and EJPB is by this ranking
one of the leading journals in the area of pharmaceutics and biopharmaceutics.
To point out some major changes for the last year, EJPB joined forces
with the European Association of Pharmaceutical Biotechnology (EAPB),
and followed up the section dedicated to Pharmaceutical Biotechnology.
The section has experienced an increasing flow of manuscripts since
its inception. Over the next years, we will work to increase publication
in this area of pharmaceutical research of increasing importance.
While soliciting manuscripts dealing with all aspects of pharmaceutical
biotechnology, including discovery, developmental and regulatory
aspects, we are at the same time continuing to identify experts
in the field that will volunteer as reviewers. To assist us in the
process of enhancing our reviewer database, we are asking the submitting
authors to identify experts in the field that may be serving as
reviewers. This will help us tremendously to both smoothen and speed
up the review process.
To strengthen the journals international orientation Prof. Jean-Christoph
Leroux from the Faculty of Pharmacy at the University of Montreal,
Canada was appointed as a new acting editor.
Also in 2006 EJPB changed to the Elsevier Electronic Submission
System (EES), for which we got in majority very positive feedback
from our authors and reviewers. With this change the number of manuscripts
we received has increased tremendously by more than 100%. The current
rejection rate is above 60% and it is anticipated that this number
will further increase in 2007. Please note that EJPB will publish
only innovative papers of highest quality and of high scientific
impact.
For the year 2007 we plan some improvements as well as a few minor
changes.
In the world of electronic exchanges of scientific publications
EJPB has abandoned the old concept of regional responsible editors.
This means that all our editors will take care about papers from
all over the world. For the printed issues the following changes
will take place. The liked “thesis sections”, in which
we announce recent published PhD work, will from now on only be
available in the electronic version, and is accessible online via
the journals website or ScienceDirect. The “instructions for
authors” will be published only once at the beginning of each
volume, they are also available online.
Furthermore we plan to introduce a new section called “State
of the art in …” These articles will be written be eminent
scientists, to publish a short analysis of a topic in pharmaceutics
and biopharmaceutics, and pharmaceutical biotechnology in a tutorial
manner, including data and a short selection of relevant references.
The new “State of the art in …” articles will
be seen as complementary to the classical Review articles.
The Editorial Team, in the USA, Canada, Europe and Japan is looking
forward to the year 2007 for your and with your support.
Dr. Michael Möller (Associate-Editor)
Prof. Gerrit Borchard (Section Editor Biotechnology)
Prof. Robert Gurny (Editor-in-Chief)
From
the Editor’s office
That
was then…
It was in October 1999 when we discussed the scope of EAPB: what
exactly is ‘Pharma Biotechnology’? Who are our ‘clients’?
How can we address both academia and the corporate world? How can
we combine expertise and experts in the field of pharma and biotech
in one organisation?
This is now…
EAPB has evolved into a professional organisation not merely bridging
pharma and biotech but integrating both aspects of modern drug development
into a field in its own right. Its membership – both personal
and corporate – has increased steadily over the years, with
members joining from both European and extra-European countries,
underlining the true international character of this organisation.
EAPB today is the representative for Pharma Biotechnology within
the European Federation of Biotechnology (EFB), and it continues
to be involved in numerous scientific conferences, seminars and
events. It was therefore a logical step to adapt a scientific journal
as a tool to extend EAPB’s ability for scientific exchange
and discussion.
The Journal…
The European Journal of Pharmaceutics and Biopharmaceutics is a
scientific publication held in high esteem by researchers in academia
and industry. The Journal is dedicated to providing a medium for
publication of novel and innovative research as well as review articles
in the various fields of pharmaceutics, biopharmaceutics and pharma
biotechnology. It is this combination of topics, and the quality
of contributed papers, which makes the Journal unique among its
peers. I would like to invite you, members of EAPB, to submit your
recent findings and share your expert opinion with your colleagues.
It’s your Journal. Use it.
Gerrit Borchard, Ph.D.
Section editor, Pharmaceutical Biotechnology
gerrit.borchard@pharm.unige.ch
|
